Infliximab for induction of remission in Crohn's disease

The primary objective is to assess the efficacy and safety of infliximab for induction of remission in patients with active CD.

This is a protocol.

Health topics:

Published:

3 April 2017

Authors:

Deol N, Nguyen TM, Parker CE, Khanna R, Feagan BG, MacDonald JK, Jairath V

Primary Review Group:

Print
PDF
Citation
Deol N, Nguyen TM, Parker CE, Khanna R, Feagan BG, MacDonald JK, Jairath V. Infliximab for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2017, Issue 4. Art. No.: CD012623. DOI: 10.1002/14651858.CD012623